Eric Murphy, Alterome CEO
Alterome raises $132M to take next-gen cancer drugs aimed at the 'undruggable' into clinic
With a new $132 million in hand, Alterome Therapeutics is finally divulging what it’s working on.
The oncology company will be using its Series B …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
